Last reviewed · How we verify
KHK2375
At a glance
| Generic name | KHK2375 |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (PHASE2)
- Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KHK2375 CI brief — competitive landscape report
- KHK2375 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI